Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma.[1] Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.[1]

Retifanlimab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetProgrammed cell death protein 1 (PD-1)
Clinical data
Trade namesZynyz
Other namesAEX-1188, INCMGA-00012, MGA-012, retifanlimab-dlwr
AHFS/Drugs.comZynyz
MedlinePlusa623017
License data
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6456H9934N1702O2032S46
Molar mass145381.13 g·mol−1

It was approved for medical use in the United States in March 2023.[1][2][3][4][5]

Medical uses

edit

Retifanlimab is indicated for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma.[1][2][6]

History

edit

The US Food and Drug Administration (FDA) evaluated the safety and efficacy of retifanlimab based on PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study evaluating 65 participants with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for advanced disease.[2]

The FDA granted the application for retifanlimab priority review, fast track, and orphan drug designations.[2]

Society and culture

edit
edit

In February 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zynyz, intended for the treatment of Merkel cell carcinoma.[7] The applicant for this medicinal product is Incyte Biosciences Distribution B.V.[7]

Names

edit

Retifanlimab is the international nonproprietary name.[8]

References

edit
  1. ^ a b c d e "Zynyz- retifanlimab-dlwr injection". DailyMed. 22 March 2023. Archived from the original on 1 July 2023. Retrieved 20 November 2023.
  2. ^ a b c d "FDA grants accelerated approval to retifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cell carcinoma". U.S. Food and Drug Administration (FDA). 22 March 2023. Archived from the original on 23 March 2023. Retrieved 22 March 2023.   This article incorporates text from this source, which is in the public domain.
  3. ^ "Incyte Announces FDA Approval of Zynyz (retifanlimab-dlwr) for the Treatment of Metastatic or Recurrent Locally Advanced Merkel Cell Carcinoma (MCC)" (Press release). Incyte. 22 March 2023. Archived from the original on 23 March 2023. Retrieved 22 March 2023 – via Business Wire.
  4. ^ "MacroGenics Earns $15 Million Milestone Following U.S. FDA Approval of Zynyz (retifanlimab-dlwr)" (Press release). MacroGenics. 22 March 2023. Archived from the original on 23 March 2023. Retrieved 22 March 2023 – via GlobeNewswire.
  5. ^ Kang C (June 2023). "Retifanlimab: First Approval". Drugs. 83 (8): 731–737. doi:10.1007/s40265-023-01884-7. PMID 37184754. S2CID 258687035.
  6. ^ "Drug Approval Package: Zynyz". U.S. Food and Drug Administration (FDA). 19 April 2023. Archived from the original on 20 November 2023. Retrieved 20 November 2023.
  7. ^ a b "Zynyz EPAR". European Medicines Agency (EMA). 22 February 2024. Retrieved 24 February 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  8. ^ World Health Organization (2020). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 83". WHO Drug Information. 34 (1). hdl:10665/339768.
edit